InNexus Biotechnology, Inc.
OTC: IXSBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Angela Giannoccaro
- Headquarters
- Vancouver, Canada
- IPO year
- 2005
- Market cap
- $12.6K
- Website
- http://www.innexusbiotech.com/
Loading IXSBF…
Loading profile data…Frequently asked questions about IXSBF
What does InNexus Biotechnology, Inc. (IXSBF) do?
InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their b...
Where does IXSBF trade?
InNexus Biotechnology, Inc. (IXSBF) trades on the Other OTC.
What sector is IXSBF in?
InNexus Biotechnology, Inc. (IXSBF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of InNexus Biotechnology, Inc.?
Angela Giannoccaro is the chief executive officer of InNexus Biotechnology, Inc. (IXSBF).
Where is InNexus Biotechnology, Inc. headquartered?
InNexus Biotechnology, Inc. is headquartered in Canada.
Does IXSBF pay a dividend?
InNexus Biotechnology, Inc. (IXSBF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IXSBF go public?
InNexus Biotechnology, Inc. (IXSBF) completed its initial public offering in 2005.